|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
23.10.25 - 22:03
|
Anika to Issue Third Quarter 2025 Financial Results on Wednesday, November 5, 2025 (GlobeNewswire EN)
|
|
|
BEDFORD, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its third quarter 2025 financial results before the opening of the market on Wednesday, November 5, 2025, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights....
|
|
|
01.10.25 - 06:30
|
Biotech Stocks Rebound After Hours Amid Broader Sector Tailwinds (RTTNews)
|
|
|
Biotech stocks posted strong after-hours gains Tuesday, with several small-cap names rebounding despite limited news flow. Broader sentiment may have been supported by Pfizer's announcement of U.S. drug price cuts and a $70 billion investment in domestic manufacturing. Ovid Therapeutics, NeuroOne Medical, PepGen, Reviva Pharmaceuticals, and Anika Therapeutics all saw notable moves following mixed regular session action....
|
|
|
|
|
|
|
|
|
|
|
|
|
08.09.25 - 11:24
|
BaFin warnt vor Identitätsmissbrauch zulasten der CAM Alternatives GmbH sowie der AltamarCAM Partners Gruppe in WhatsApp-Gruppen (BaFin)
|
|
|
Die Finanzaufsicht BaFin warnt vor WhatsApp-Gruppen, die angeblich von der CAM Alternatives GmbH, Köln, bzw. der AltamarCAM Partners Gruppe, Madrid, zu der die CAM Alternatives GmbH gehört, betrieben werden. Diese WhatsApp-Gruppen werden angeblich von Luis Santos sowie seinen angeblichen Assistentinnen Anika Sommer, Clara Weingart, Jana Kuhn, Helena Meyer, Franziska Brandt, Lea Koch, Laura Fischer, Seva Hartwig, Lina Sommer und Ena Sophie Wagner geleitet....
|
|
|
05.09.25 - 11:03
|
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
|
|
|
BEDFORD, Mass., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that on September 2, 2025, Anika granted non-statutory stock options (“Options”) covering an aggregate of 2,500 shares of common stock at a per share exercise price of $9.15, which equaled the closing price of common stock on the Nasdaq Global Select Market on the grant date, to one newly hired non-executive employee. The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, was approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with Nasdaq Listing Rule 5635(c)(4), was made as a material inducement to the grantee's acceptance of employment with Anika as a component of the grantee's employment compensation....
|
|
|
|
|
|
|
|
|
07.08.25 - 14:15
|
Anika Therapeutics: Unterschätzter Orthopädie-Spezialist (Sharedeals)
|
|
|
Trotz schwacher Kursentwicklung in den vergangenen Jahren bietet Anika Therapeutics mittlerweile ein attraktives Chance-Risiko-Verhältnis für langfristige Anleger. Mit einem innovativen Produktportfolio, das auf hyaluronsäurebasierten Lösungen aufbaut, erschließt das Unternehmen milliardenschwere Märkte in der orthopädischen Schmerztherapie und Geweberegeneration. Fokus auf regenerative Medizin Anika Therapeutics, mit Sitz in Bedford, Massachusetts, wurde 1992 gegründet und ist auf die […]
The post Anika Therapeutics: Unterschätzter Orthopädie-Spezialist first appeared on sharedeals.de....
|
|